In mice and in rats, reduced levels of the growth hormone secretagogue receptor (GHS-R1a) results in reduced body weight and lower levels of serum insulin-like growth factor I (IGF-I). However, the mechanism leading to these impairments has not been elucidated. Studies in primary cultures of pituitary cells from very young mice have shown that GHS-R1a agonists, including ghrelin, increase expression of the pituitary-specific transcription factor (Pit-1) that is critical for differentiation of pituitary cells into somatotrophs, lactotrophs, and thyrotrophs. Hence, we hypothesized that ablation of Ghsr would reduce Pit-1 expression and as a consequence reduce growth hormone (GH) production explaining the lower body weight of GhsrÀ/À mice. Here, we now show that Pit-1 mRNA levels are significantly lower in the pituitary gland of GhsrÀ/À mice compared to wild-type littermates and also with advancing age. This Pit-1 loss is associated with reduced GH mRNA and fewer GH producing cells. To determine whether reduced GH is caused by reduced expression of Pit-1 in GhsrÀ/À mice, we also measured prolactin (PRL) expression in the pituitary gland and in the circulation. PRL mRNA was significantly reduced in GhsrÀ/À mice compared to wild-type littermates and fewer cells expressed PRL. The reduction in expression of both GH and PRL is consistent with a Pit-1 regulated pathway and demonstrates that the GHS-R has an important role in the pituitary gland as a modulator of Pit-1 expression and provides a possible mechanism to explain the lower plasma IGF-1 and modestly reduced body weight exhibited by GhsrÀ/ À mice. We also believe that lower systemic and lymphoid hormone expression may also account, in part, for the enhanced thymic involution and reduced thymic output in GhsrÀ/À mice.
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Introduction
The GHS-R was first characterized and expression cloned using a small molecule, MK-0677 that was designed to restore the amplitude of episodic GH release in elderly subjects to that of young adults (Howard et al., 1996; Patchett et al., 1995; Pong et al., 1996; Smith et al., 1997) . GHS-R produces two transcripts that encode GHS-R1a and GHS-R1b (Howard et al., 1996) ; the former is a seven transmembrane domain (TM) G-protein coupled receptor, whereas the latter is a truncated form that lacks TM-VI and TM-VII and is localized in the nucleus rather than on the plasma membrane (Smith et al., 2005) . Besides being expressed in cells that regulate GH pulse amplitude, the GHS-R is expressed in regions of the brain involved in memory and cognitive function (Guan et al., 1997) , in the pancreas (Howard et al., 1996) and in immune cell subsets (Dixit et al., 2004 (Dixit et al., , 2007 .
By fractionating tissue extracts and assaying for GHS-R1a activation in cells, Kojima and associates identified a 28-aminoacid octanoylated peptide agonist produced by enteroendocrine cell in the stomach and named this endogenous GHS-R1a agonist ghrelin. Amongst peptide agonists ghrelin is unique because octanoylation on Ser3 is essential for binding and activation of GHS-R1a (Dixit et al., 2007) . Sun and colleagues (Sun et al., 2004) produced GhsrÀ/À mice and showed they were refractory to the GH-releasing and orexigenic properties of ghrelin, which confirmed unambiguously that GHS-R1a was a biologically relevant receptor for ghrelin.
In addition to GH release, GHS-R1a agonists stimulate PRL release from primary cultures of female rat pituitary cells (Cheng 
